Why Are Health Experts Warning You About the FDA’s Shocking Rejection of Moderna's New Flu Vaccine?

Local health experts are expressing deep concern following the U.S. Food and Drug Administration's (FDA) refusal to review Moderna's application for a new flu vaccine developed using mRNA technology. This decision has been labeled a “shock” by many in the health community and raises alarms about the future of vaccine development in the United States.

On Tuesday, Moderna, a biotechnology company based in Cambridge, announced that the FDA rejected its application, which had undergone rigorous clinical trials involving 40,000 participants. These trials indicated that the new mRNA flu vaccine was more effective in adults aged 50 and older compared to the standard flu shots currently in use.

“It came as a shock to not just the company, but to all of us,” said Dr. Jerry Avorn, a professor of medicine at Harvard Medical School. He noted that the FDA's decision arrived “at the very last minute, at the 11th hour,” after a substantial effort from Moderna to conduct a comprehensive randomized trial.

The FDA's refusal to file the application was articulated in a letter from Dr. Vinay Prasad, the FDA's vaccine director, who stated that the trial did not meet the agency's standards for an “adequate and well-controlled trial.” Specifically, the FDA believed the new vaccine should have been compared to “the best-available standard of care” at the time, which was not done according to the agency's expectations. Feedback provided to Moderna in 2024 indicated a preference for using a different flu vaccine, specifically designed for seniors, in trials involving participants aged 65 and older.

Despite this, Moderna contends that the FDA approved the trial's original design. The company also referenced additional data from a separate trial that compared its new vaccine against a licensed high-dose flu shot used for seniors. Moderna's CEO, Stephane Bancel, emphasized that the FDA “did not identify any safety or efficacy concerns” regarding their product and criticized the decision as not serving the shared goal of advancing innovative medicine in the U.S.

The FDA's move is particularly unusual, as it is rare for the agency to refuse to even review a new vaccine application. This decision has raised eyebrows among experts, who fear it could deter pharmaceutical companies from pursuing similar innovative vaccines in the future. “The fact that such a draconian and really very, very unusual decision not even to review the application can be made this late in the process is worrisome for, frankly, all drug companies—and all doctors and all patients,” Avorn added. “It calls into question this time-honored process.”

Experts have clarified that the FDA's refusal does not suggest any immediate safety or efficacy concerns regarding the new vaccine. According to Maggie Lind, an assistant professor of epidemiology at Boston University, the FDA’s statement points to a need for “more information” rather than raising red flags about the vaccine's safety or effectiveness.

The implications of this decision extend beyond just Moderna. Michael Ulrich, an associate professor at Boston University’s School of Public Health and School of Law, criticized the FDA's actions, suggesting that after initially approving the study design, the agency should not later claim that it was not conducted according to their expectations. “That’s a waste of time, money, and resources on the part of the pharmaceutical company,” Ulrich stated.

Moderna is seeking an urgent meeting with the FDA to discuss the matter further. The company has also submitted applications for the vaccine’s approval in Europe, Canada, and Australia.

Under the leadership of Health Secretary Robert F. Kennedy Jr., the FDA has exhibited an increased level of scrutiny concerning vaccines, particularly those utilizing mRNA technology, which had previously gained significant attention due to their role in combating COVID-19. In the past year, the FDA has also rolled back recommendations regarding COVID-19 shots and has imposed new warnings on leading mRNA vaccines.

Historically, the FDA has allowed vaccine manufacturers to update annual flu shots more efficiently by demonstrating that they trigger an adequate immune response without the need for lengthy trials. However, a memo from Prasad indicated that this streamlined approach would no longer be permitted, leading to criticism from over a dozen former FDA commissioners.

The repercussions of the FDA's recent actions could potentially delay the introduction of mRNA flu vaccines and stifle future innovations in vaccine technology. As Moderna navigates this unexpected hurdle, the health community watches closely, recognizing the broader implications for vaccine development in the U.S.